AVXL logo

AVXL
Anavex Life Sciences Corp

24,353
Mkt Cap
$385.51M
Volume
1.01M
52W High
$13.99
52W Low
$2.86
PE Ratio
-8.95
AVXL Fundamentals
Price
$4.36
Prev Close
$4.16
Open
$4.17
50D MA
$4.25
Beta
1.47
Avg. Volume
1.44M
EPS (Annual)
-$0.5438
P/B
3.04
Rev/Employee
$0.00
$656.50
Loading...
Loading...
News
all
press releases
Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen
Wall Street Zen upgraded Anavex Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·12d ago
News Placeholder
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
Here is how Anavex Life Sciences (AVXL) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Zacks·12d ago
News Placeholder
Q2 EPS Forecast for Anavex Life Sciences Boosted by Analyst
Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) - Investment analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of Anavex Life Sciences in a note issued to...
MarketBeat·12d ago
News Placeholder
Brokers Issue Forecasts for AVXL Q1 Earnings
Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) - Equities researchers at HC Wainwright issued their Q1 2027 EPS estimates for shares of Anavex Life Sciences in a note issued to investors on...
MarketBeat·13d ago
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL)
D. Boral Capital reiterated a "buy" rating and set a $24.00 price objective on shares of Anavex Life Sciences in a research note on Monday...
MarketBeat·15d ago
News Placeholder
Anavex Life Sciences Q1 Earnings Call Highlights
Anavex Life Sciences (NASDAQ:AVXL) executives used the company's fiscal 2026 first-quarter earnings call to outline regulatory next steps for oral blarcamesine in early Alzheimer's disease and to...
MarketBeat·15d ago
News Placeholder
Anavex Life Sciences (NASDAQ:AVXL) Releases Earnings Results, Beats Expectations By $0.04 EPS
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.06) earnings per share for the quarter, topping...
MarketBeat·15d ago
News Placeholder
Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference
Anavex Life Sciences (NASDAQ:AVXL) outlined its strategy to develop oral, precision-medicine therapies for central nervous system (CNS) diseases during a presentation at the J.P. Morgan Healthcare...
MarketBeat·1mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·2mo ago
<
1
2
...
>

Latest AVXL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.